cyc 202 has been researched along with ha14-1 in 1 studies
Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (ha14-1) | Trials (ha14-1) | Recent Studies (post-2010) (ha14-1) |
---|---|---|---|---|---|
979 | 7 | 393 | 104 | 0 | 31 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, L; Chen, Z; Cheng, JQ; Ren, Y; Reuther, GW; Wang, HG; Woods, NT; Wu, J | 1 |
1 other study(ies) available for cyc 202 and ha14-1
Article | Year |
---|---|
Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.
Topics: Amino Acid Substitution; Apoptosis; bcl-X Protein; Benzopyrans; Cell Line; Cell Survival; Chlorpropamide; Chromones; Down-Regulation; Elafin; Enzyme Activation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; MAP Kinase Signaling System; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Myeloid Progenitor Cells; Neoplasm Proteins; Nitriles; Oncogene Protein p21(ras); Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Up-Regulation | 2007 |